Overview
Retrospective observational studies face challenges in determining appropriate treatment sequences, especially for multi-cancer cohorts. This study aims to assess the performance of a disease-agnostic treatment sequencing heuristic for deriving lines of therapy (LOT) within a biomarker-defined, multi-tumor cohort.
Utilizing data from the Flatiron Health-Foundation Medicine Clinico-genomic Database, the research evaluates the feasibility of this approach in aligning with National Comprehensive Cancer Network (NCCN) recommendations and accurately reflecting treatment patterns across diverse cancer types.
Why this matters
This study represents a significant step forward in treatment sequence determination across multiple cancer types. By demonstrating the feasibility and effectiveness of a disease-agnostic treatment sequencing heuristic, the research offers a standardized approach to defining clinically appropriate LOTs in a multi-tumor patient cohort. With implications for real-world treatment-related analyses, particularly concerning biomarker-defined therapies and immune checkpoint inhibitor usage, this approach has the potential to improve treatment decision-making and patient outcomes in clinical practice.
View the abstract on the ISPOR website
More from Flatiron Health at ISPOR US 2024
Read about Flatiron's accepted research and presence at ISPOR US.
